Communiqués Adverum Biotechnologies, Inc.

Actions

ADVM

US00773U2078

Temps réel estimé Cboe BZX Autres places de cotation 20:01:27 10/06/2024			Varia. 5j.	Varia. 1 janv.
7,45 ^USD	+1,36 %		-4,19 %	-1,37 %

16/05	Transcript : Adverum Biotechnologies, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM
09/05	Adverum Biotechnologies, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05	AQ
Adverum Biotechnologies: Q1 Earnings Snapshot	09/05	AQ
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights	09/05	AQ
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	06/05	AQ
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences	03/05	AQ
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting	25/04	AQ
Adverum Biotechnologies: Q4 Earnings Snapshot	18/03	AQ
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	18/03	AQ
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	28/02	AQ
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12/02	AQ
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	08/02	AQ
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	05/02	AQ
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024	01/02	AQ
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer	29/01	AQ
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society	07/12	AQ
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference	28/11	AQ
Adverum Biotechnologies: Q3 Earnings Snapshot	09/11	AQ
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights	09/11	AQ
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023	06/11	AQ
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors	06/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Adverum Biotechnologies, Inc.

Actions

ADVM

US00773U2078

Communiqués

Filtres